CD86 and cancer: The DEX maintained the immunostimulatory molecules of mature DCs, such as p‐MHC and CD86, for endogenous T cell activation, while the modification of αCD3 and αEGFR on DEX could connect the T cells and cancer cells by simultaneously binding to CD3 (expressed on T cell surface) and cancer cell‐associated EGFR.